摘要
在西方人群中,凝血因子V莱顿(FVL)的携带关联是目前最常见的血栓形成倾向。FVL是由凝血因子V (FV)基因编码中的单基因点突变引起,FV会导致终身的促凝血因子状态,增加静脉血栓栓塞(VTE)的风险,也许会致命。它认为,21000年前人类发生突变,今天,西方人群中有3%-15%是携带者。一种潜在的危险突变如FVL,如果不刨根问底的话,应当是罕见的;在人类的进化过程中,这种突变应该是选择性地减少。因此,为了繁衍,FVL一定赋予了携带者一种进化优势。低风险的大量出血和增加的繁殖力也许给了携带者一种优势。本文中我们对简单背景进行了更新,并且讨论了可能的进化利弊。
关键词: 莱顿第五因子,进展,优势,产科并发症,出血,APC阻力
Current Medicinal Chemistry
Title:On the Evolutionary Advantage of Coagulation Factor V Leiden (FVL)
Volume: 22 Issue: 32
Author(s): P.G. Lindqvist
Affiliation:
关键词: 莱顿第五因子,进展,优势,产科并发症,出血,APC阻力
摘要: Carriership of coagulation factor V Leiden (FVL) is by far the most common thrombophilia in Western populations. FVL is caused by a single point mutation in the gene coding for coagulation factor V (FV) causing a lifelong procoagulatory state with an increased risk of venous thromboembolism (VTE) which might be fatal. It is believed that the mutation occurred in one person 21,000 years ago and today 3% to 15% of the Western populations are carriers. A potentially dangerous mutation such as FVL ought to be rare and should have been reduced, if not eradicated, by selection during the course of human evolution. Thus, FVL must confer the carriers with an evolutionary advantage in order to be so prevalent. Lower risk of profuse bleeding and increased fecundity might give carriers an advantage. In this paper we give an updated short background and discuss possible evolutionary advantages and disadvantages.
Export Options
About this article
Cite this article as:
P.G. Lindqvist , On the Evolutionary Advantage of Coagulation Factor V Leiden (FVL), Current Medicinal Chemistry 2015; 22 (32) . https://dx.doi.org/10.2174/0929867322666151001121707
DOI https://dx.doi.org/10.2174/0929867322666151001121707 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design Drug Repositioning: A Smart Approach for Combating SARS-CoV-2
Anti-Infective Agents Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation
Current Cardiology Reviews Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Adjunctive Therapy for Percutaneous Revascularization in Acute Myocardial Infarction
Current Pharmaceutical Design Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Pharmacometabonomics Technique to Identify Warfarin Response Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Blood Pressure Lowering Treatment in Patients with Carotid Artery Stenosis
Current Hypertension Reviews Paradoxical Thrombotic Effects of Aspirin: Experimental Study on 1000 Animals
Cardiovascular & Hematological Disorders-Drug Targets The No-Reflow Phenomenon in the Coronary Circulation
Cardiovascular & Hematological Agents in Medicinal Chemistry Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology